Inclusion Criteria:
For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
- Advanced melanoma (Stage III/Stage IV)
- Histologically confirmed diagnosis
- Treatment decision for nivolumab monotherapy or nivolumab/ipilimumab combination
therapy has already been taken
For Cohort 3: (Recruitment ended by 08/31/2020)
- Primary diagnosis of advanced melanoma after complete surgical tumor resection and no
evidence of disease
- Treatment decision for adjuvant nivolumab therapy has already been taken
Exclusion Criteria:
For Cohort 1 and 2: (Recruitment ended by 02/20/2020)
- Current primary diagnosis of a cancer other than advanced melanoma, that requires
systemic or other treatment or has not been treated curatively (as per discretion of
the investigator)
- Previous treatment with nivolumab, for nivolumab monotherapy cohort only
- Current active participation in an interventional clinical trial
For Cohort 3: (Recruitment ended by 08/31/2020)
- Current diagnosis of persisting advanced melanoma or a cancer other than advanced
melanoma that requires systemic or other treatment or has not been treated curatively
(as per discretion of the investigator)
- Current active participation in an interventional clinical trial
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
